Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity

Diabetes

Volumn 56, Issue 5, 2007, Pages 1341-1349

  Aerts, Johannes M ^a   Ottenhoff, Roelof ^b   Powlson, Andrew S ^c   Grefhorst, Aldo ^a   Van Eijk, Marco ^b   Dubbelhuis, Peter F ^b   Aten, Jan ^a   Kuipers, Folkert ^d   Serlie, Mireille J ^a   Wennekes, Tom ^e   Sethi, Jaswinder K ^c   O'Rahilly, Stephen ^c   Overkleeft, Hermen S ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Macrozyme   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; GLYCOSYLATED HEMOGLOBIN; IMINOSUGAR; INSULIN; N (5' ADAMANTANE 1' YLMETHOXY)PENTYL 1 DEOXYNOJIRIMYCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; IN VITRO STUDY; IN VIVO CULTURE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPOGENESIS; LIVER; MALE; METABOLIC REGULATION; MOUSE; MUSCLE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TISSUE LEVEL;

1-DEOXYNOJIRIMYCIN; 3T3 CELLS; ADAMANTANE; ADIPOCYTES; ANIMALS; CERAMIDES; ENZYME INHIBITORS; GLUCOSE INTOLERANCE; GLUCOSYLCERAMIDES; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; HUMANS; INSULIN; LIVER; MICE; MICE, INBRED C57BL; MICE, OBESE; PANCREAS; SIGNAL TRANSDUCTION;

EID: 34248205140     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1619     Document Type: Article

References (36)

1. Unger RH: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144:5159-5165, 2003
2. Savage DB, Petersen KF, Shulman GI: Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 45:828-833, 2005
3. Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW: The role of intramuscular lipid in insulin resistance. Acta Physiol Scand 178:373-383, 2003
4. Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ: Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25-31, 2004
5. Summers SA: Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45:42-72, 2006
6. Kolter T, Proia RL, Sandhoff K: Combinatorial ganglioside biosynthesis. J Biol Chem 277:25859-25862, 2002
7. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes, J Clin Invest 115:1111-1119, 2005
8. Peraldi P, Spiegelman B: TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 182:169-175, 1998
9. Miura A, Miura A, Kajita K, Ishizawa M, Kanoh Y, Kawai Y, Natsume Y, Sakuma H, Yamamoto Y, Yasuda K, Ishizuka T: Inhibitory effect of ceramide on insulin-induced protein kinase Czeta translocation in rat adipocytes. Metabolism 52:19-24, 2003
10. Stratford S, Hoehn KL, Liu F, Summers SA: Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 279:26608-36615, 2004
11. Powell DJ, Turban S, Gray A, Hajduch E, Hundal HS: Intracellular ceramide synthesis and PKCzeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J 382:619-629, 2004
12. Ruvolo PP: Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47:383-392, 2003
13. Allende ML, Proia RL: Lubricating cell signalling pathways with gangliosides. Curr Opin Struct Biol 12:587-592, 2002
14. Rebbaa A, Hurh J, Yamamoto H, Kersey DS, Bremer EG: Ganglioside GM3 inhibition of EGF receptor mediated signal transduction. Glycobiology 6:399-406, 1996
15. Tagami S, Tagami S, Inokuchi Ji J, Kabayama K, Yoshimura H, Kitamura F, Uemura S, Ogawa C, Ishii A, Saito M, Ohtsuka Y, Sakaue S, Igarashi Y: Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 277:3085-3092, 2002
16. Yamashita T, Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, Kono M, Tsuji S, Daniotti JL, Werth N, Sandhoff R, Sandhoff K, Proia RL.: Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A 100:3445-3449, 2003
17. Kabayama K, Kabayama K, Sato T, Kitamura F, Uemura S, Kang BW, Igarashi Y, Inokuchi J: TNF alpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3. Glycobiology 15:21-29, 2004
18. Shayman JA, Abe A, Hiraoka M: A turn in the road: how studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity. Glycoconj J 20:25-32, 2004
19. Aerts JM, Hollak C, Boot R, Groener A: Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 358:905-914, 2003
20. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK, O'Rahilly S: Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. Mol Endocrinol 15:1729-1738, 2001
21. Overkleeft HS, Renkema GH, Neele J, Vianello P, Hung IO, Strijland A, van der Burg AM, Koomen GJ, Pandit UK, Aerts JM: Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem 273:26522-26527, 1998
22. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509, 1957
23. Taketomi T, Hara A, Uemura K, Sugiyama E: Rapid method of preparation of lysoglycosphingolipids and their confirmation by delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J Biochem (Tokyo) 120:573-579, 1996
24. Neville DC, Coquard V, Priestman DA, te Vruchte DJ, Sillence DJ, Dwek RA, Platt FM, Butters TD: Analysis of fluorescently labeled glycosphingolipid- derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. Anal Biochem 331:275-282, 2004
25. Van Weely S, Van Leeuwen MB, Jansen ID, De Bruijn MA, Brouwer-Kelder EM, Schram AW, Sa Miranda MC, Barranger JA, Petersen EM, Goldblatt J, Stotz H, Schwarzmann G, Sandhoff K, Svennerholm L, Erikson A, Tager JM, Aerts JM: Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta 1096:301-311, 1991
26. Andersson U, Butters TD, Dwek RA, Platt FM: N- butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59:821-829, 2000
27. Andersson U, Reinkensmeier G, Butters TD, Dwek RA, Platt FM: Inhibition of glycogen breakdown by iminosugars in vitro and in vivo. Biochem Pharmacol 67:697-705, 2004
28. Ebina Y, Edery M, Ellis L, Standring D, Beaudoin J, Roth R, Rutter WJ: Expression of a functional human insulin receptor from a cloned cDNA in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 82:8014-8018, 1985
29. van Dijk TH, Boer TS, Havinga R, Stellaard F, Kuipers F, Reijngoud DJ: Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots. Anal Biochem 322:1-13, 2003
30. Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, Romijn JA, Groot PH, Reijngoud DJ, Kuipers F: Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab 289:E829-E838, 2005
31. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A: Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet 355:1481-1485, 2000
32. Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DM, Hammer RE, Hamra FK, Matern S, Russell DW: Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest 116:2985-2994, 2006
33. Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, Wennekes T, Aerts JM: Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem 282:1305-1312, 2006
34. Scott LJ, Spencer CM: Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 59:521-549, 2000
35. Fleet GW, Fellows LE, Winchester B: Plagiarizing plants: amino sugars as a class of glycosidase inhibitors. Ciba Found Symp 154:112-122, 1990
36. Nojima H, Kimura I, Chen FJ, Sugihara Y, Haruno M, Kato A, Asano N: Antihyperglycemic effects of N-containing sugars from Xanthocercis zambesiaca, Morus bombycis, Aglaonema treubii, and Castanospermum australe in streptozotocin-diabetic mice. J Nat Prod 61:397-400, 1998